PDS Biotechnology(NASDAQ) PDSB

PDS Biotechnology develops medicines that help the immune system fight cancer and infectious diseases. Its main products aim to treat cancers linked to viruses and prevent serious infections. These therapies are designed for patients with limited treatment options and for public health needs.

Lab Bench to Bedside: What PDS Makes

• PDS0101 (Cancer Immunotherapy): In clinical trials for head and neck, cervical, and HPV-related cancers; no revenue yet.
• PDS0102, PDS0103, PDS0104 (Cancer Pipeline): Early-stage therapies for prostate, breast, ovarian, colorectal, lung, and skin cancers; preclinical stage.
• PDS01ADC (Targeted Oncology): Experimental drug combining immune activation and targeted delivery for solid tumors; currently in early-stage clinical trials.
• PDS0201, PDS0202, PDS0203 (Infectious Disease Vaccines): Preclinical vaccines for tuberculosis, influenza, and COVID-19; no commercial sales.
• Technology Platforms: Versamune and Infectimune, which help activate immune cells to target disease; used across all products.

Growth Spurts and Science Sprints

• Launched VERSATILE-003 Phase 3 trial for PDS0101 in March 2025.
• Expanded PDS01ADC Phase 2 trial in colorectal cancer in July 2025.
• Secured exclusive global license with Merck KGaA for PDS01ADC in December 2022.
• Raised $11 million in equity financing in February 2025 and $20 million in debt financing in April 2025.
• Collaborates with National Institutes of Health, Mayo Clinic, and MD Anderson for research and clinical trials.

Why PDS Is a Bit Different

PDS focuses on therapies that activate the body’s own immune cells, aiming to address cancers with few treatment options. Its technology platforms are designed for use in both cancer and infectious disease. The company partners with major research institutions to advance its pipeline.

Five Things You Need to Know

• No revenue reported for Q2 2025, Q2 2024, or Q2 2023.
• Net loss was $9.4 million in Q2 2025, up 13% year-over-year.
• Operating expenses fell 12% to $7.6 million in Q2 2025.
• Cash and equivalents dropped 23% to $31.9 million by June 30, 2025.
• Substantial doubt exists about ability to continue as a going concern as of June 2025.

Bottom Line

PDS remains focused on developing immune-based therapies for cancer and infectious diseases. The company faces ongoing financial challenges but continues to advance its clinical pipeline through partnerships and new trials.